BACKGROUND: A recent comprehensive review concluded that additional research is needed to determine the optimal use of aspirin for cancer prevention. OBJECTIVE: To assess associations between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer risk. DESIGN: Population-based, case-control study. SETTING: Northern Denmark. PATIENTS: Patients with first-time colorectal cancer in northern Denmark between 1994 and 2011. Population control participants were selected by risk set sampling. MEASUREMENTS: Data on drug use, comorbid conditions, and history of colonoscopy were obtained from prescription and patient registries. Use of low-dose aspirin (75 to 150 mg) and nonaspirin NSAIDs was defined according to type, estimated dose, duration, and consistency of use. RESULTS: Among 10 280 case patients and 102 800 control participants, the adjusted odds ratios (ORs) for colorectal cancer associated with ever use (≥2 prescriptions) of low-dose aspirin and nonaspirin NSAIDs were 1.03 (95% CI, 0.98 to 1.09) and 0.94 (CI, 0.90 to 0.98), respectively. Continuous long-term use (≥5 years) of low-dose aspirin was associated with a 27% reduction in colorectal cancer risk (OR, 0.73 [CI, 0.54 to 0.99]), whereas the overall OR for cumulative long-term use (continuous or noncontinuous) was close to unity. Nonaspirin NSAID use was associated with a substantial reduction in colorectal cancer risk, particularly for long-term, high-intensity use (average defined daily dose ≥0.3) of agents with high cyclooxygenase-2 selectivity (OR, 0.57 [CI, 0.44 to 0.74]). LIMITATIONS: Data were unavailable on over-the-counter purchases of high-dose aspirin and low-dose ibuprofen or NSAID dosing schedules, there were several comparisons, and the authors were unable to adjust for confounding by some risk factors. CONCLUSION: Long-term, continuous use of low-dose aspirin and long-term use of nonaspirin NSAIDs were associated with reduced colorectal cancer risk. Persons who continuously used low-dose aspirin comprised only a small proportion of the low-dose aspirin users. PRIMARY FUNDING SOURCE: Danish Cancer Society, Aarhus University Research Foundation.
BACKGROUND: A recent comprehensive review concluded that additional research is needed to determine the optimal use of aspirin for cancer prevention. OBJECTIVE: To assess associations between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer risk. DESIGN: Population-based, case-control study. SETTING: Northern Denmark. PATIENTS: Patients with first-time colorectal cancer in northern Denmark between 1994 and 2011. Population control participants were selected by risk set sampling. MEASUREMENTS: Data on drug use, comorbid conditions, and history of colonoscopy were obtained from prescription and patient registries. Use of low-dose aspirin (75 to 150 mg) and nonaspirin NSAIDs was defined according to type, estimated dose, duration, and consistency of use. RESULTS: Among 10 280 case patients and 102 800 control participants, the adjusted odds ratios (ORs) for colorectal cancer associated with ever use (≥2 prescriptions) of low-dose aspirin and nonaspirin NSAIDs were 1.03 (95% CI, 0.98 to 1.09) and 0.94 (CI, 0.90 to 0.98), respectively. Continuous long-term use (≥5 years) of low-dose aspirin was associated with a 27% reduction in colorectal cancer risk (OR, 0.73 [CI, 0.54 to 0.99]), whereas the overall OR for cumulative long-term use (continuous or noncontinuous) was close to unity. Nonaspirin NSAID use was associated with a substantial reduction in colorectal cancer risk, particularly for long-term, high-intensity use (average defined daily dose ≥0.3) of agents with high cyclooxygenase-2 selectivity (OR, 0.57 [CI, 0.44 to 0.74]). LIMITATIONS: Data were unavailable on over-the-counter purchases of high-dose aspirin and low-dose ibuprofen or NSAID dosing schedules, there were several comparisons, and the authors were unable to adjust for confounding by some risk factors. CONCLUSION: Long-term, continuous use of low-dose aspirin and long-term use of nonaspirin NSAIDs were associated with reduced colorectal cancer risk. Persons who continuously used low-dose aspirin comprised only a small proportion of the low-dose aspirin users. PRIMARY FUNDING SOURCE: Danish Cancer Society, Aarhus University Research Foundation.
Authors: Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman Journal: Expert Rev Clin Pharmacol Date: 2017-04-10 Impact factor: 5.045
Authors: Evan M Hill; Raymond M Esper; Ananda Sen; Becky R Simon; Muhammad N Aslam; Yan Jiang; Michael K Dame; Shannon D McClintock; Justin A Colacino; Zora Djuric; Max S Wicha; William L Smith; Dean E Brenner Journal: J Nutr Biochem Date: 2019-05-24 Impact factor: 6.048
Authors: Chul Kim; Xuehong Zhang; Andrew T Chan; Howard D Sesso; Nader Rifai; Meir J Stampfer; Jing Ma Journal: Cancer Epidemiol Date: 2016-08-06 Impact factor: 2.984